Old arthritis drug takes on tough cancers in early trial
NCT ID NCT04997993
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial is testing leflunomide, a drug currently used for rheumatoid arthritis, in people with advanced solid tumors that have a PTEN gene change or HER2-negative breast cancer. The study has two parts: first, finding a safe dose and checking for side effects; second, looking for any signs that the drug shrinks tumors. Only 23 participants will be enrolled, so results will be very preliminary.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Leflunomide (a drug typically used for rheumatoid arthritis, taken as a daily pill)
What this could lead to
If it works, this could point toward a new treatment option for certain advanced cancers that have a PTEN gene change or HER2-negative breast cancer.
What could go wrong
This is a very early, small Phase 1 trial with only 23 participants. The main goal is safety and dosing, not yet proving the drug works against cancer. Side effects may be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Icahn School of Medicine at Mount Sinai
RECRUITINGNew York, New York, 10029, United States
Contact